

The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease

A Randomized, Controlled Clinical Trial

Iain Bressendorff,^{1,2} Ditte Hansen ,² Morten Schou,³ Andreas Pasch,^{4,5} and Lisbet Brandt¹

Abstract

Background and objectives Serum calcification propensity is a novel functional test that quantifies the functionality of the humeral system of calcification control. Serum calcification propensity is measured by T₅₀, the time taken to convert from primary to secondary calciprotein particle in the serum. Lower T₅₀ represents higher calcification propensity and is associated with higher risk of cardiovascular events and death in patients with ESKD. Increasing magnesium in serum increases T₅₀, but so far, no clinical trials have investigated whether increasing serum magnesium increases serum calcification propensity in subjects with ESKD.

Design, setting, participants, & measurements We conducted a single-center, randomized, double-blinded, parallel group, controlled clinical trial, in which we examined the effect of increasing dialysate magnesium from 1.0 to 2.0 mEq/L for 28 days compared with maintaining dialysate magnesium at 1.0 mEq/L on T₅₀ in subjects undergoing hemodialysis for ESKD. The primary end point was the value of T₅₀ at the end of the intervention.

Results Fifty-nine subjects were enrolled in the trial, and of these, 57 completed the intervention and were analyzed for the primary outcome. In the standard dialysate magnesium group, T₅₀ was 233±81 minutes (mean±SD) at baseline (mean of days -7 and 0) and 229±93 minutes at follow-up (mean of days 21 and 28), whereas in the high dialysate magnesium group, T₅₀ was 247±69 minutes at baseline and 302±66 minutes at follow-up. The difference in T₅₀ between the two groups at follow-up (primary analysis) was 73 minutes (between-group difference; 95% confidence interval, 30 to 116; *P*<0.001), and the between-group difference in serum magnesium was 0.88 mg/dl (95% confidence interval, 0.66 to 1.10; *P*=0.001).

Conclusions Increasing dialysate magnesium increases T₅₀ and hence, decreases calcification propensity in subjects undergoing maintenance hemodialysis.

Clin J Am Soc Nephrol 13: 1373–1380, 2018. doi: <https://doi.org/10.2215/CJN.13921217>

Introduction

Patients with ESKD have a 20-fold higher risk of cardiovascular mortality compared with the general population (1). Arterial stiffness, at least partially due to vascular calcification, has been associated with cardiovascular mortality in ESKD (2). Disturbances in the mineral and bone metabolism seen in ESKD are believed to result in accelerated vascular calcification by inducing an osteogenic dedifferentiation of vascular smooth muscle cells into a bone-like phenotype characterized by deposition of calcified mineral matrix and increased stiffness (3). Thus, measures to prevent calcification might reduce arterial stiffness and consequently, cardiovascular mortality.

Serum calcification propensity (T₅₀) is a novel functional test (4) that measures the time point of conversion from primary calciprotein particles to secondary calciprotein particles in serum, and it is believed to reflect the propensity toward ectopic

calcification. Secondary calciprotein particles (but not primary calciprotein particles) have been shown to induce vascular calcification *in vitro* (5), and low T₅₀ has been shown to be associated with cardiovascular events and all-cause mortality in ESKD (6), CKD stages 3 and 4 (7), and kidney transplant recipients (8,9). Increasing T₅₀ might, therefore, prevent calcification and reduce the incidence of cardiovascular events. Addition of magnesium (Mg) to serum increases T₅₀ *in vitro* (4), and thus, Mg treatment may be useful in improving T₅₀. Increasing dialysate Mg is a simple, inexpensive, and effective way of increasing serum Mg, and it might, therefore, also be effective in increasing T₅₀.

To study this further, we conducted a randomized, double-blind, controlled clinical trial, in which we tested whether increasing dialysate Mg from 1.0 to 2.0 mEq/L would affect T₅₀ in patients with ESKD on maintenance hemodialysis (HD). We hypothesized

¹Department of Cardiology, Nephrology, and Endocrinology, Nordsjællands Hospital, Hillerød, Denmark; ²Departments of Nephrology and ³Cardiology, Herlev and Gentofte Hospital, Herlev, Denmark; ⁴Department of Biomedical Research, University of Bern, Bern, Switzerland; and ⁵Calciscon AG, Bern, Switzerland

Correspondence:

Dr. Iain Bressendorff, Department of Cardiology, Nephrology and Endocrinology, Nordsjællands Hospital, Dyrehavevej 29, DK-3400 Hillerød, Denmark. Email: iain@bressendorff.com

that increasing dialysate Mg for 28 days would increase T_{50} and that T_{50} would return to baseline 14 days after returning to standard dialysate Mg.

Materials and Methods

Design

This trial was an investigator-initiated, randomized, double-blind, parallel-group, controlled clinical trial that was conducted from March to June of 2017 at the dialysis wards of Nordsjællands Hospital (Hillerød, Denmark). Subjects were randomized in a 1:1 ratio to 28 days of treatment with either standard dialysate Mg (1.0 mEq/L) or high dialysate Mg (2.0 mEq/L). After the 28 days of intervention, subjects returned to their regular dialysis regimen with standard dialysate Mg of 1.0 mEq/L, but they were followed for another 14 days to assess any changes occurring after the intervention.

Subjects were numbered consecutively as they entered the trial and allocated to treatment using a computer-generated, block-randomized randomization list. Treatment allocation (*i.e.*, the product number printed on the dialysate containers) was printed and placed in sealed opaque envelopes, which were opened by the staff at the dialysis wards before the dialysis session on day 0.

For the purpose of the trial, 6-L plastic containers with dialysate (MTN Neubrandenburg GmbH) were used throughout the interventional period of the trial. Containers with standard dialysate Mg had concentrations of Mg and chloride of 1.0 and 108.5 mEq/L, respectively, whereas containers with high dialysate Mg had concentrations of Mg and chloride of 2.0 and 109.5 mEq/L, respectively. Apart from this, all other components of the dialysate were identical (*i.e.*, sodium, 138.0 mEq/L; potassium, 2.0 mEq/L; calcium [Ca], 2.5 mEq/L; bicarbonate [HCO_3], 32.0 mEq/L; and acetate, 3.0 mEq/L). The containers were identical in appearance, except for information regarding dialysate Mg concentration and product number. Dialysate concentrations were obscured with a black felt pen such that nurses were blinded to dialysate Mg concentrations, and during the dialysis treatment, the dialysate containers were positioned such that the product number was hidden from the physicians and subjects, thus ensuring that all physicians, nurses, and subjects were blinded to treatment allocation during the trial.

For the duration of the trial, no changes were to be made to medications that might influence the bone and mineral metabolism (*i.e.*, phosphate [PO_4] binders, Ca supplements, active or inactive vitamin D analogs, calcimimetics, or intravenous iron) unless strictly necessary and only on approval from the primary investigator. We prespecified serum Mg >4.4 mg/dl as an upper safety limit, such that any subjects exceeding this threshold would immediately return to their regular dialysis regimen with dialysate Mg of 1.0 mEq/L.

Outcomes

The primary end point was the value of T_{50} at the end of the intervention period (mean of days 21 and 28) between the two treatment groups (see below). Secondary end points were change in T_{50} from baseline to the end of the intervention period, changes in markers of mineral and

bone metabolism at the end of the intervention and their changes from baseline, and incidence of adverse events.

Subjects

All patients undergoing in-center HD at the dialysis wards were screened, and eligible patients were approached in conjunction with their regular HD treatment and offered participation in the trial. Inclusion criteria were age ≥ 18 years old, treatment with maintenance in-center HD for >3 months, serum Mg <2.9 mg/dl, negative pregnancy test and actively using contraceptive therapy for women of childbearing age (contraceptive pills, estrogen depots, or intrauterine device), and ability to give written informed consent. Exclusion criteria were treatment with peritoneal dialysis; serum intact parathyroid hormone (PTH) >620 pg/ml; previous parathyroidectomy; dialysate Ca of >2.50 mEq/L; current treatment with Mg-containing medication or supplements; diseases or conditions that, in the opinion of the primary investigator, would prevent participation in or completion of the trial; participation in other clinical trials; and pregnancy or breastfeeding.

Ethics

The trial is in compliance with the Helsinki Declaration, and it was approved by the Danish National Committee on Biomedical Research Ethics and the Danish Data Protection Agency. All subjects gave written informed consent before participation in the trial. The trial was registered at ClinicalTrials.gov (NCT02977117) on November 30, 2016.

Laboratory Analyses

Nonfasting blood samples were drawn before dialysis sessions on days -7, 0, 7, 14, 21, 28, 35, and 42. Serum samples for T_{50} and fetuin-A were centrifuged at 3000 rpm for 10 minutes at 4°C, after which they were stored at -80°C until the time of analysis. All other samples were analyzed at the local Department of Clinical Biochemistry. Serum samples for T_{50} were analyzed as previously described (4). Fetuin-A and intact PTH were analyzed using a polyclonal rabbit anti-human antiserum (10) and ADVIA Centaur intact PTH assay (Siemens Healthineers, Erlangen, Germany), respectively.

Statistical Analyses and Sample Size Calculation

The primary end point was the value of T_{50} at the end of the intervention period (mean of measurements on days 21 and 28; see below); the difference in the primary end-point was calculated using an unpaired *t* test.

The mean and SD for predialysis T_{50} in patients with ESKD treated with HD have previously been reported to be approximately 250 and 55 minutes, respectively (11). We considered a between-group difference in T_{50} of 40 minutes to be clinically relevant. A sample size of 30 subjects per group was sufficient to obtain a power of 80% in an unpaired *t* test with a significance of 5%. We anticipated a dropout rate of 15% in each group, and therefore, we planned to include a total of 72 subjects randomized in a ratio of 1:1.




Figure 1. | Participant flow diagram/Consolidated Standards Of Reporting Trials (CONSORT) study diagram. Ca, calcium; Mg, magnesium.

Paired *t* tests were used to analyze within-group changes, and unpaired *t* tests were used to analyze between-group differences. PTH was logarithmically transformed to achieve a normal distribution and later, back transformed to calculate effect size and confidence intervals. Changes over time within each group for T_{50} , Mg, PO_4 , ionized Ca, HCO_3 , albumin, and logarithmically transformed PTH were analyzed using linear mixed models with compound symmetry and time as the repeated measure from measurements on days -7 , 0 , 7 , 14 , 21 , and 28 .

For the purpose of the data analysis, baseline was defined as the mean of measurements on days -7 and 0 , and follow-up was defined as the mean of measurements on days 21 and 28 . This was done to minimize the potential effects of fluctuations in variables associated with T_{50} (*i.e.*, PO_4 , Ca, Mg, fetuin-A, *etc.*), which were unknown before conducting the trial.

We used a complete patient analysis (*i.e.*, participants for whom final outcome data were not available were dropped from the analyses). Statistical analyses were performed blinded to treatment allocation. All tests were two sided, with $P < 0.05$ considered statistically significant.

Results

All 136 patients undergoing treatment with in-center HD at Nordsjællands Hospital (Hillerod, Denmark) were screened for eligibility. Of these patients, 62 matched the entry criteria for the trial, and 59 gave their consent to participate. We were unable to recruit the planned 72 subjects, because there were not enough patients matching trial criteria at Nordsjællands Hospital; additionally, it was unfeasible to expand the trial to another site.

During the trial intervention, one subject withdrew consent on day 9 (high-dialysate Mg group), and one subject died on day 11 (high-dialysate Mg group), thus leaving 57 subjects for the final data analysis (Figure 1). In addition, two subjects died during the 14-day postintervention observational period (one from each treatment group). Baseline characteristics for the two treatment groups are described in Table 1. We had data completeness for the primary end point for all 57 subjects who completed the 28 days of intervention.

After initiation of the intervention on day 0, there was a statistically significant increase in serum Mg in the high-dialysate Mg group, which reached a new plateau on day 7

Table 1. Baseline characteristics of participants who completed a clinical trial assessing the effect of increasing dialysate magnesium concentration on serum calcification propensity measured by T₅₀

| Demographics | Total, n=57 | Standard Dialysate Magnesium, n=29 | High Dialysate Magnesium, n=28 |
|---|------------------|------------------------------------|--------------------------------|
| Sex, men/women | 35/22 | 19/10 | 16/12 |
| Age, yr | 73 (63–80) | 73 (54–78) | 73 (63–82) |
| Body mass index, m ² /kg | 25.3 (21.9–29.7) | 26.2 (22.9–30.4) | 24.3 (21.0–28.2) |
| White race (%) | 55 (97) | 29 (100) | 26 (93) |
| African race (%) | 2 (3) | 0 (0) | 2 (7) |
| Cause of ESKD (%) | | | |
| Diabetes mellitus | 15 (26) | 10 (34) | 5 (18) |
| Hypertension | 14 (25) | 8 (28) | 6 (21) |
| Glomerular diseases | 4 (7) | 1 (3) | 3 (11) |
| Polycystic kidney disease | 8 (14) | 4 (14) | 4 (14) |
| Interstitial nephritis | 1 (2) | 0 (0) | 1 (4) |
| Other | 8 (14) | 4 (14) | 4 (14) |
| Unknown | 7 (12) | 2 (7) | 5 (18) |
| Comorbidities (%) | | | |
| Diabetes mellitus type 1 | 2 (4) | 2 (7) | 0 (0) |
| Diabetes mellitus type 2 | 16 (28) | 10 (34) | 6 (21) |
| Hypertension | 45 (79) | 25 (86) | 20 (71) |
| Dyslipidemia | 26 (46) | 12 (41) | 14 (50) |
| Coronary artery disease | 20 (35) | 12 (41) | 8 (29) |
| Heart failure | 10 (18) | 4 (14) | 6 (21) |
| Peripheral artery disease | 10 (18) | 7 (24) | 3 (11) |
| Previous stroke | 11 (19) | 2 (7) | 9 (32) |
| Inflammatory disease | 6 (11) | 1 (3) | 5 (18) |
| Chronic obstructive pulmonary disease | 8 (14) | 1 (3) | 7 (25) |
| Dialysis modality (%) | | | |
| Hemodialysis | 29 (51) | 18 (62) | 11 (39) |
| Hemodiafiltration | 28 (49) | 11 (38) | 17 (61) |
| Dialysis access (%) | | | |
| Catheter | 16 (28) | 10 (34) | 6 (21) |
| Fistula | 41 (72) | 19 (66) | 22 (79) |
| Dialysis filter (%) | | | |
| Polyflux 140H | 1 (2) | 0 (0) | 1 (4) |
| Polyflux 170H | 30 (52) | 15 (52) | 15 (54) |
| Polyflux 210H | 26 (46) | 14 (48) | 12 (43) |
| Dialysis vintage, mo | 32 (18–70) | 30 (13–59) | 39 (21–99) |
| Dialysis session length, min | 210 (210–240) | 210 (210–240) | 210 (206–240) |
| Weekly dialysis time, min | 630 (578–720) | 630 (630–720) | 630 (540–720) |
| Weekly Kt/V | 4.08 (3.63–4.40) | 3.90 (3.60–4.53) | 4.13 (3.75–4.36) |
| Dialysis access blood flow, ml/min | 310 (300–350) | 300 (288–350) | 330 (300–350) |
| Anuric (%) | 25 (44) | 13 (45) | 12 (43) |
| Urine volume for nonanuric subjects, ml/d | 1250 (600–1875) | 1525 (600–1975) | 925 (525–1750) |
| Medication (%) | | | |
| Calcium carbonate | 18 (32) | 9 (31) | 9 (32) |
| Sevelamer | 40 (70) | 19 (66) | 21 (75) |
| Lanthanum | 17 (30) | 10 (34) | 7 (25) |
| Alfacalcidol | 40 (70) | 17 (59) | 23 (82) |
| Cinacalcet | 14 (25) | 7 (24) | 7 (25) |
| Intravenous iron | 32 (56) | 17 (59) | 15 (54) |
| Erythropoietin stimulating agent | 50 (88) | 27 (93) | 23 (82) |
| Warfarin | 3 (5) | 3 (10) | 0 (0) |

Medians and interquartile ranges are given for continuous values, and absolute numbers and percentages are given for categorical values.

and was maintained at this level until the end of the intervention on day 28, whereas serum Mg was unchanged in the standard-dialysate Mg group (Figure 2A). Serum Mg was significantly higher in the high-dialysate Mg group compared with the standard-dialysate Mg group at the end of the intervention (between-group difference in serum Mg at follow-up was 0.88 mg/dl; 95% confidence interval, 0.66 to 1.10; $P=0.001$). On completion of the intervention and return to dialysate Mg of 1.0 mEq/L, serum Mg

returned to baseline levels in the high-dialysate Mg group (Figure 2A).

In parallel to the increase in serum Mg, there was a statistically significant increase in T₅₀ on day 7 in the high-dialysate Mg group, which was maintained for the duration of the intervention (Figure 2B), whereas T₅₀ remained stable in the standard-dialysate Mg group. Again, T₅₀ was significantly higher at the end of the intervention in the high-dialysate Mg group compared with the




Figure 2. | Increasing dialysate magnesium (Mg) increases serum Mg (A) and (T₅₀; B) while decreasing serum phosphate (PO₄; C) and serum intact parathyroid hormone (PTH; E), but does not affect serum ionized calcium (Ca; D). Black circles indicate dialysate Mg of 1.0 mEq/L; white circles indicate dialysate Mg of 2.0 mEq/L.

standard-dialysate Mg group (between-group difference at follow-up was 73 minutes; 95% confidence interval 30 to 116; $P < 0.001$), and on returning to dialysate Mg of 1.0 mEq/L, T₅₀ returned to baseline levels in the high-dialysate Mg group (Figure 2B).

There were no significant changes in serum ionized Ca during the intervention (Figure 2D), but PO₄ decreased immediately in the high-dialysate Mg group, after which there was a gradual return to baseline values (Figure 2C); although there was no statistically significant difference

between the two groups at the end of the intervention, there was a significant change over time for PO₄ within the high-dialysate Mg group (Table 2). Also, PTH decreased significantly during the intervention in the high-dialysate Mg group and showed a significant change over time (Figure 2E, Table 2), although PTH was not significantly different at the end of the intervention between the two groups (Table 2). Fetuin-A, HCO₃, and albumin were not significantly different between the two treatment groups at the end of the intervention (Table 2).

Table 2. Effects of increasing dialysate magnesium on T₅₀ and related biomarkers

| Variable | Baseline | Follow-Up | Change from Baseline to Follow-Up (95% CI) | Between-Group Difference at Follow-Up (95% CI) | P Value for Difference at Follow-Up |
|-------------------------------|---------------|---------------|--|--|-------------------------------------|
| T₅₀, min | | | | 73 (30 to 116) | 0.001 |
| Standard dialysate Mg | 233±81 | 229±93 | -4 (-26 to 17) | | |
| High dialysate Mg | 247±69 | 302±66 | 54 (31 to 78) ^a | | |
| Mg, mg/dl | | | | 0.9 (0.7 to 1.1) | 0.001 |
| Standard dialysate Mg | 2.4±0.3 | 2.5±0.3 | 0.1 (-0.0 to 0.2) | | |
| High dialysate Mg | 2.4±0.4 | 3.4±0.5 | 0.9 (0.8 to 1.1) ^a | | |
| PO₄, mg/dl | | | | -0.4 (-1.0 to 0.3) | 0.24 |
| Standard dialysate Mg | 5.0±1.3 | 4.9±1.3 | -0.1 (-0.5 to 0.3) | | |
| High dialysate Mg | 4.7±0.9 | 4.5±1.0 | -0.2 (-0.6 to 0.1) ^b | | |
| Ionized Ca, mg/dl | | | | -0.0 (-0.2 to 0.1) | 0.53 |
| Standard dialysate Mg | 4.6±0.2 | 4.6±0.3 | -0.1 (-0.1 to 0.0) | | |
| High dialysate Mg | 4.6±0.4 | 4.5±0.3 | -0.0 (-0.1 to 0.0) | | |
| Fetuin-A, g/L | | | | 0.01 (-0.03 to 0.05) | 0.55 |
| Standard dialysate Mg | 0.31±0.07 | 0.31±0.07 | 0.00 (-0.01 to 0.02) | | |
| High dialysate Mg | 0.32±0.06 | 0.32±0.07 | 0.00 (-0.01 to 0.01) | | |
| HCO₃, mEq/L | | | | -0 (-1 to 1) | 0.79 |
| Standard dialysate Mg | 25±2 | 25±2 | 0 (-0 to 1) | | |
| High dialysate Mg | 24±3 | 25±2 | 1 (0 to 1) ^c | | |
| Albumin, g/dl | | | | 0.0 (-0.2 to 0.2) | 0.87 |
| Standard dialysate Mg | 3.2±0.4 | 3.3±0.4 | 0.1 (-0.0 to 0.1) ^c | | |
| High dialysate Mg | 3.3±0.3 | 3.3±0.4 | 0.0 (-0.1 to 0.1) | | |
| PTH, pg/ml | | | | -21% (-41% to 6%) | 0.12 |
| Standard dialysate Mg | 278 (199–359) | 311 (207–347) | 14% (1% to 28%) | | |
| High dialysate Mg | 328 (206–387) | 238 (165–366) | -21% (-28% to -13%) ^b | | |

Baseline and follow-up values are described as mean±SD or median and interquartile range. Changes from baseline to follow-up are described as mean change with 95% CI. Change over time was analyzed using linear mixed models. Baseline was defined as the mean of measurements on days -7 and 0, and follow-up was defined as the mean of measurements on days 21 and 28. 95% CI, 95% confidence interval; T₅₀, serum calcification propensity; Mg, magnesium; PO₄, phosphate; Ca, calcium; HCO₃, bicarbonate; PTH, intact parathyroid hormone.

^aChange from baseline to end of follow-up is significant at $P<0.001$.

^bChange from baseline to end of follow-up is significant at $P<0.01$.

^cChange from baseline to end of follow-up is significant at $P<0.05$.

During the intervention, four subjects experienced adverse events (two in each treatment group), and nine experienced serious adverse events (two in the standard-dialysate Mg group and seven in the high-dialysate Mg group), including one death in the high-dialysate Mg group (Supplemental Table 1). During the postintervention observational phase of the trial, there occurred another two adverse events (both in the high-dialysate Mg group) and five serious adverse events (two in the standard-dialysate Mg group and three in the high-dialysate Mg group), including two deaths (one in each treatment group) (Supplemental Table 1). None of these events were attributed to the study intervention, and no subjects were withdrawn from the trial due to serum Mg >4.4 mg/dl.

Discussion

The main result of this trial is that increasing dialysate Mg from 1.0 to 2.0 mEq/L increases (*i.e.*, improves) T₅₀ after 28 days of treatment. This change was observed immediately and in parallel to an increase in serum Mg but with no significant between-group differences at follow-up to other factors known to affect T₅₀ (PO₄, Ca, fetuin-A, albumin, and HCO₃), indicating that the increase in T₅₀ was indeed caused by the increase in serum Mg. We did, however, also

observe a change over time for within-group changes in PO₄ and PTH in the high-dialysate Mg group, and it is possible that changes to these factors or related unmeasured factors contributed at least partially to the changes in T₅₀ in addition to the increase in serum Mg.

The effect of increasing serum Mg on T₅₀ is likely caused by delaying the time until precipitation of amorphous Ca/PO₄ particles (12). This should result in reduced size and increased stability of primary calciprotein particles, which would delay the time until formation of secondary calciprotein particles (4). Theoretically, any intervention that reduces the serum concentrations of calcification promoters (*e.g.*, PO₄ or Ca) or increases serum concentrations of calcification inhibitors (*e.g.*, Mg or fetuin-A) should also stabilize primary calciprotein particles and thereby, increase T₅₀ (4). Therefore, it seems likely that increasing serum Mg is just one of several options to improve T₅₀ and that other interventions might also be effective in achieving this goal (*e.g.*, PO₄ binders).

In line with previous observations, PTH decreased in the high-dialysate Mg group in within-group analyses, possibly reflecting a calcimimetic effect in which Mg stimulates the Ca-sensing receptor of the parathyroid glands (13). This is consistent with a previous *in vitro* study, which found that increasing Mg reduces the secretion and transcription

of PTH from parathyroid cells as well as increases the transcription of the Ca-sensing receptor (14). The decrease in PTH might also account for the acute decrease in PO_4 observed in the high-dialysate Mg group. It is likely that any changes to serum PO_4 and PTH would also affect T_{50} , and thus, the effect of increasing dialysate Mg on T_{50} might not exclusively be due to the increase in serum Mg. However, we found no differences in PO_4 or PTH between the two treatment groups at follow-up, and the trial was not designed to investigate changes in PO_4 and PTH. Therefore, these results should be interpreted with caution.

Several *in vitro* studies have shown that Mg inhibits calcification induced by Ca and PO_4 , but a recent study has shown that the effect is due to inhibition of amorphous Ca/ PO_4 and hydroxyapatite formation and not intracellular mechanisms as has previously been proposed (15). Similarly, secondary calciprotein particles induce calcification *in vitro*, and Mg prolongs the time until formation of secondary calciprotein particles in serum (4). This suggests that the inverse association between serum Mg and cardiovascular events (16) and the *in vivo* inhibitory effect of Mg supplementation on vascular calcification (17) might be due to the inhibitory effect of Mg on amorphous Ca/ PO_4 transformation (12) and thus, inhibition of hydroxyapatite and calciprotein particle formation, which in turn, might prevent the formation of calcification. More studies are needed to further examine this association in humans.

In this trial, there were more adverse events in the intervention group compared with the control group. However, because none of the events were of a nature typically associated with symptomatic hypermagnesemia (*i.e.*, hypotension, bradycardia, syncope, flushing, or neuromuscular inhibition [18]), we find it more likely that the observed difference in adverse events is due to mere chance rather than an effect of the intervention itself. Given the relatively small sample size and short duration of the trial, it is not possible to rule out any long-term or rare complications. Because no subjects were withdrawn from the trial due to serum Mg >4.4 mg/dl, symptomatic hypermagnesemia (which typically occurs at serum Mg >4.8 mg/dl) would not be expected as long as serum Mg is <2.9 mg/dl before treatment initiation. Nonetheless, it seems prudent to monitor serum Mg in any patients treated with increased concentrations of dialysate Mg.

Although we consider T_{50} a novel and promising treatment target, a limitation of this trial is that T_{50} is a surrogate marker associated with cardiovascular and all-cause mortality and is not a hard clinical end point in itself. Whether increasing dialysate Mg has any effect on hard clinical end points will have to be investigated in an adequately powered clinical trial with a long period of follow-up. We were unable to recruit the planned 72 subjects to the trial, and of the 60 subjects who were expected to complete the trial, only 57 completed the entire trial. Given the narrow confidence intervals around the effect estimate, it is highly unlikely that this has affected the main result of the trial. Also, the trial was of a short duration, and it is possible that longer treatment duration might have affected the results of this trial. However, any profound change to these results seems unlikely given that T_{50} returned to baseline levels immediately after the intervention (*i.e.*, days 35 and 42). Although there was an

imbalance between treatment with HD and hemodiafiltration at baseline between the two treatment groups, previous research has shown that there is no difference in T_{50} reduction with hemodiafiltration compared with HD (11). Also, there is a risk of false positive findings when performing multiple statistical comparisons, which might have affected the results.

The strengths of the trial include its randomized, double-blinded, and controlled study design. Also, the intravenous route of Mg administration ensures that there were no issues with treatment nonadherence on behalf of the trial participants.

In conclusion, increasing dialysate Mg from 1.0 to 2.0 mEq/L for 28 days significantly increased T_{50} in subjects with ESKD treated with HD. No incidences of serum Mg >4.4 mg/dl occurred during the trial, and we did not consider any adverse events to be related to the intervention. Further study is needed to investigate whether increasing dialysate Mg improves clinical outcomes in patients with ESKD.

Acknowledgments

The authors would like to thank all of the nurses and staff at the dialysis wards at Nordsjællands Hospital (Hillerød, Denmark) for their tremendous help with conducting the trial. Hanne Laursen of Baxter-Gambro was especially helpful during the planning and initiation of the trial, and Charlotte Bjernved Nielsen kindly prepared the randomization material.

Disclosures

A.P. is one of the coinventors of the serum calcification propensity (T_{50}) test and is the CEO and cofounder of Calciscon AG (Bern, Switzerland), which specializes in performing the T_{50} test. The other authors have no conflicts of interest.

References

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 32 [Suppl 3]: S112–S119, 1998
2. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. *Nephrol Dial Transplant* 18: 1731–1740, 2003
3. Paloiian NJ, Giachelli CM: A current understanding of vascular calcification in CKD. *Am J Physiol Renal Physiol* 307: F891–F900, 2014
4. Pasch A, Farese S, Gräber S, Wald J, Richtering W, Floege J, Jahn-Dechent W: Nanoparticle-based test measures overall propensity for calcification in serum. *J Am Soc Nephrol* 23: 1744–1752, 2012
5. Aghagolzadeh P, Bachtler M, Bijarnia R, Jackson C, Smith ER, Odermatt A, Radpour R, Pasch A: Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor- α . *Atherosclerosis* 251: 404–414, 2016
6. Pasch A, Block GA, Bachtler M, Smith ER, Jahn-Dechent W, Arampatzis S, Chertow GM, Parfrey P, Ma X, Floege J: Blood calcification propensity, cardiovascular events, and survival in patients receiving hemodialysis in the EVOLVE trial. *Clin J Am Soc Nephrol* 12: 315–322, 2017
7. Smith ER, Ford ML, Tomlinson LA, Bodenham E, McMahon LP, Farese S, Rajkumar C, Holt SG, Pasch A: Serum calcification propensity predicts all-cause mortality in predialysis CKD. *J Am Soc Nephrol* 25: 339–348, 2014
8. Keyzer CA, de Borst MH, van den Berg E, Jahn-Dechent W, Arampatzis S, Farese S, Bergmann IP, Floege J, Navis G, Bakker SJ, van Goor H, Eisenberger U, Pasch A: Calcification propensity and survival among renal transplant recipients. *J Am Soc Nephrol* 27: 239–248, 2016

9. Dahle DO, Åsberg A, Hartmann A, Holdaas H, Bachtler M, Jenssen TG, Dionisi M, Pasch A: Serum calcification propensity is a strong and independent determinant of cardiac and all-cause mortality in kidney transplant recipients. *Am J Transplant* 16: 204–212, 2016
10. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA: Association between human fetuin-A and the metabolic syndrome: Data from the Heart and Soul Study. *Circulation* 113: 1760–1767, 2006
11. Dekker M, Pasch A, van der Sande F, Konings C, Bachtler M, Dionisi M, Meier M, Kooman J, Canaud B: High-flux hemodialysis and high-volume hemodiafiltration improve serum calcification propensity. *PLoS One* 11: e0151508, 2016
12. Termine JD, Peckauskas RA, Posner AS: Calcium phosphate formation in vitro. II. Effects of environment on amorphous-crystalline transformation. *Arch Biochem Biophys* 140: 318–325, 1970
13. McGonigle RJ, Weston MJ, Keenan J, Jackson DB, Parsons V: Effect of hypermagnesemia on circulating plasma parathyroid hormone in patients on regular hemodialysis therapy. *Magnesium* 3: 1–7, 1984
14. Rodríguez-Ortiz ME, Canalejo A, Herencia C, Martínez-Moreno JM, Peralta-Ramírez A, Perez-Martinez P, Navarro-González JF, Rodríguez M, Peter M, Gundlach K, Steppan S, Passlick-Deetjen J, Muñoz-Castañeda JR, Almadén Y: Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. *Nephrol Dial Transplant* 29: 282–289, 2014
15. Ter Braake ADTP, Tinnemans PT, Shanahan CM, Hoenderop JGJ, de Baaij JHF: Magnesium prevents vascular calcification in vitro by inhibition of hydroxyapatite crystal formation. *Sci Rep* 8: 2069, 2018
16. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y: Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. *Kidney Int* 85: 174–181, 2014
17. Diaz-Tocados JM, Peralta-Ramirez A, Rodríguez-Ortiz ME, Raya AI, Lopez I, Pineda C, Herencia C, Montes de Oca A, Vergara N, Steppan S, Pendon-Ruiz de Mier MV, Buendía P, Carmona A, Carracedo J, Alcalá-Díaz JF, Frazao J, Martínez-Moreno JM, Canalejo A, Felsenfeld A, Rodríguez M, Aguilera-Tejero E, Almadén Y, Muñoz-Castañeda JR: Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats. *Kidney Int* 92: 1084–1099, 2017
18. Jahnhen-Dechent W, Ketteler M: Magnesium basics. *Clin Kidney J* 5 [Suppl 1]: i3–i14, 2012

Received: December 15, 2017 **Accepted:** June 21, 2018

Published online ahead of print. Publication date available at www.cjasn.org.

See related editorial, “Magnesium Concentration in Dialysate: Is Higher Better?,” on pages 1309–1310.

This article contains supplemental material online at <http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.13921217/-/DCSupplemental>.